利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.016 秒)

    Arylamino purine derivatives, preparation method and pharmaceutical use thereof
    2.
    发明授权
    Arylamino purine derivatives, preparation method and pharmaceutical use thereof 有权
    芳基氨基嘌呤衍生物，其制备方法和药物用途

    公开(公告)号：US09096601B2

    公开(公告)日：2015-08-04

    申请号：US13699960

    申请日：2010-12-23

    申请人： Shengyong Yang ,  Yuquan Wei

    发明人： Shengyong Yang ,  Yuquan Wei

    IPC分类号： C07D473/16 ,  C07D473/18 ,  C07D473/32

    CPC分类号： C07D473/32 ,  C07D473/16 ,  C07D473/18

    摘要： Arylamino purine derivatives represented by formula I and their preparation method are disclosed, wherein each substituent is defined as in the description. The derivatives have an inhibitory effect on non-small cell lung cancer with deletion mutation of exon 19 or L858R point mutation of exon 21 in epidermal growth factor receptor (EGFR).

    摘要翻译： 公开了由式I表示的芳基氨基嘌呤衍生物及其制备方法，其中每个取代基如描述中所定义。 该衍生物对表皮生长因子受体（EGFR）中外显子19或外显子21的L858R点突变的缺失突变的非小细胞肺癌具有抑制作用。

    Oxazolidinone compounds and their uses in preparation of antibiotics
    3.
    发明授权
    Oxazolidinone compounds and their uses in preparation of antibiotics 有权
    恶唑烷酮化合物及其在制备抗生素中的应用

    公开(公告)号：US08946436B2

    公开(公告)日：2015-02-03

    申请号：US14126999

    申请日：2012-06-15

    申请人： Youfu Luo ,  Zhenling Wang ,  Yuquan Wei ,  Funeng Geng

    发明人： Youfu Luo ,  Zhenling Wang ,  Yuquan Wei ,  Funeng Geng

    IPC分类号： C07D401/00 ,  C07D413/10 ,  C07D413/14 ,  C07D401/04

    CPC分类号： C07D413/10 ,  C07D401/04 ,  C07D413/14

    摘要： The invention belongs to the field of medicaments, and particularly relates to oxazolidinone compounds and their uses in the preparation of antibiotics. A technical problem to be solved by the invention is to provide new oxazolidinone compounds having the structure represented by Formula I. The oxazolidinone compounds of the invention, which are new compounds obtained through numerous screening, have significant antibacterial activity against bacteria such as drug-resistant staphylococcus aureus, fecal coliform bacteria, and streptococcus pneumoniae, while exhibiting low toxicity. The invention provides new options for the development and application of antibiotics.

    摘要翻译： 本发明属于药物领域，特别涉及恶唑烷酮化合物及其在制备抗生素中的用途。 本发明要解决的技术问题是提供具有由式I表示的结构的新的恶唑烷酮化合物。作为通过多次筛选获得的新化合物的本发明的恶唑烷酮化合物对抗细菌如抗药性具有显着的抗菌活性 金黄色葡萄球菌，粪大肠菌群和肺炎链球菌，同时表现出低毒性。 本发明为抗生素的开发和应用提供了新的选择。

    Arylamino Purine Derivatives, Preparation Method and Pharmaceutical Use Thereof
    4.
    发明申请
    Arylamino Purine Derivatives, Preparation Method and Pharmaceutical Use Thereof 有权
    芳基嘌呤衍生物，其制备方法及药物用途

    公开(公告)号：US20130203986A1

    公开(公告)日：2013-08-08

    申请号：US13699960

    申请日：2010-12-23

    申请人： Shengyong Yang ,  Yuquan Wei

    发明人： Shengyong Yang ,  Yuquan Wei

    IPC分类号： C07D473/32 ,  C07D473/16 ,  C07D473/18

    CPC分类号： C07D473/32 ,  C07D473/16 ,  C07D473/18

    摘要： Arylamino purine derivatives represented by formula I and their preparation method are disclosed, wherein each substituent is defined as in the description. The derivatives have an inhibitory effect on non-small cell lung cancer with deletion mutation of exon 19 or L858R point mutation of exon 21 in epidermal growth factor receptor (EGFR).

    摘要翻译： 公开了由式I表示的芳基氨基嘌呤衍生物及其制备方法，其中每个取代基如描述中所定义。 该衍生物对表皮生长因子受体（EGFR）中外显子19或外显子21的L858R点突变的缺失突变的非小细胞肺癌具有抑制作用。

    Oxazolidinone Compounds and Their Uses in Preparation of Antibiotics
    6.
    发明申请
    Oxazolidinone Compounds and Their Uses in Preparation of Antibiotics 有权
    恶唑烷酮化合物及其在制备抗生素中的用途

    公开(公告)号：US20140142144A1

    公开(公告)日：2014-05-22

    申请号：US14126999

    申请日：2012-06-15

    申请人： Youfu Luo ,  Zhenling Wang ,  Yuquan Wei ,  Funeng Geng

    发明人： Youfu Luo ,  Zhenling Wang ,  Yuquan Wei ,  Funeng Geng

    IPC分类号： C07D413/10 ,  C07D413/14

    CPC分类号： C07D413/10 ,  C07D401/04 ,  C07D413/14

    摘要： The invention belongs to the field of medicaments, and particularly relates to oxazolidinone compounds and their uses in the preparation of antibiotics. A technical problem to be solved by the invention is to provide new oxazolidinone compounds having the structure represented by Formula I. The oxazolidinone compounds of the invention, which are new compounds obtained through numerous screening, have significant antibacterial activity against bacteria such as drug-resistant staphylococcus aureus, fecal coliform bacteria, and streptococcus pneumoniae, while exhibiting low toxicity. The invention provides new options for the development and application of antibiotics.

    摘要翻译： 本发明属于药物领域，特别涉及恶唑烷酮化合物及其在制备抗生素中的用途。 本发明要解决的技术问题是提供具有由式I表示的结构的新的恶唑烷酮化合物。作为通过多次筛选获得的新化合物的本发明的恶唑烷酮化合物对抗细菌如抗药性具有显着的抗菌活性 金黄色葡萄球菌，粪大肠菌群和肺炎链球菌，同时表现出低毒性。 本发明为抗生素的开发和应用提供了新的选择。

    B cell activating factor antagonist and preparation method and use thereof
    8.
    发明授权
    B cell activating factor antagonist and preparation method and use thereof 有权
    B细胞激活因子拮抗剂及其制备方法及用途

    公开(公告)号：US09290582B2

    公开(公告)日：2016-03-22

    申请号：US13699903

    申请日：2011-05-26

    申请人： Li Yang ,  Yuquan Wei

    发明人： Li Yang ,  Yuquan Wei

    IPC分类号： C07K19/00 ,  C07K14/47 ,  C07K14/705 ,  A61K38/00 ,  A61K48/00 ,  A61K31/7088

    CPC分类号： C07K19/00 ,  A61K31/7088 ,  A61K38/00 ,  A61K48/005 ,  C07K14/4703 ,  C07K14/70578 ,  C07K2319/00 ,  C07K2319/30

    摘要： The present invention relates to the field of genetic engineering drugs, particularly to a novel B cell activating factor (BAFF) antagonist and use thereof. The technical problem to be solved by the invention is to find a new and effective selection for the prevention and treatment of autoimmune diseases. The B cell activating factor receptor antagonist is mainly obtained by the fusion of the domain 2 binding BAFF in TACI receptor and the domain binding BAFF in Br3 receptor, and it also can be fused with a Fc segment of IgG1 to obtain a new fusion protein molecule. Experiments indicate that said new fusion protein molecule has the function of BAFF antagonist, which can treat the autoimmune diseases, and supply a new and effective selection for the prevention and treatment of the autoimmune diseases.

    摘要翻译： 本发明涉及遗传工程药物领域，特别涉及一种新型B细胞激活因子（BAFF）拮抗剂及其应用。 本发明要解决的技术问题是找到一种新的有效的预防和治疗自身免疫性疾病的选择。 B细胞激活因子受体拮抗剂主要通过融合TACI受体中的结构域2结合BAFF和Br3受体结合BAFF的结构域而获得，并且还可以与IgG1的Fc区融合以获得新的融合蛋白分子 。 实验表明，所述新型融合蛋白分子具有BAFF拮抗剂的功能，可以治疗自身免疫性疾病，为预防和治疗自身免疫性疾病提供新的有效选择。

    B CELL ACTIVATING FACTOR ANTAGONIST AND PREPARATION METHOD AND USE THEREOF
    10.
    发明申请
    B CELL ACTIVATING FACTOR ANTAGONIST AND PREPARATION METHOD AND USE THEREOF 有权
    B细胞活化因子拮抗剂及其制备方法及其用途

    公开(公告)号：US20130089549A1

    公开(公告)日：2013-04-11

    申请号：US13699903

    申请日：2011-05-26

    申请人： Li Yang ,  Yuquan Wei

    发明人： Li Yang ,  Yuquan Wei

    IPC分类号： C07K19/00

    CPC分类号： C07K19/00 ,  A61K31/7088 ,  A61K38/00 ,  A61K48/005 ,  C07K14/4703 ,  C07K14/70578 ,  C07K2319/00 ,  C07K2319/30

    摘要： The present invention relates to the field of genetic engineering drugs, particularly to a novel B cell activating factor (BAFF) antagonist and use thereof. The technical problem to be solved by the invention is to find a new and effective selection for the prevention and treatment of autoimmune diseases. The B cell activating factor receptor antagonist is mainly obtained by the fusion of the domain 2 binding BAFF in TACI receptor and the domain binding BAFF in Br3 receptor, and it also can be fused with a Fc segment of IgG1 to obtain a new fusion protein molecule. Experiments indicate that said new fusion protein molecule has the function of BAFF antagonist, which can treat the autoimmune diseases, and supply a new and effective selection for the prevention and treatment of the autoimmune diseases.

    摘要翻译： 本发明涉及遗传工程药物领域，特别涉及一种新型B细胞激活因子（BAFF）拮抗剂及其应用。 本发明要解决的技术问题是找到一种新的有效的预防和治疗自身免疫性疾病的选择。 B细胞激活因子受体拮抗剂主要通过融合TACI受体中的结构域2结合BAFF和Br3受体结合BAFF的结构域而获得，并且还可以与IgG1的Fc区融合以获得新的融合蛋白分子 。 实验表明，所述新型融合蛋白分子具有BAFF拮抗剂的功能，可以治疗自身免疫性疾病，为预防和治疗自身免疫性疾病提供新的有效选择。